Home » News » Awards & Advancement » Novogen appoints Iain Ross acting CEO, reappoints him to board

Novogen appoints Iain Ross acting CEO, reappoints him to board

Monday, July 27, 2015

Novogen, a U.S.-Australian drug development company, has reappointed Iain Ross to the board. Ross, a former director of Novogen, also will become acting chief executive until a permanent appointment is made.

Ross currently is chairman of Premier Veterinary Group (formerly Ark Therapeutics), a non-executive director of Amarantus Biosciences and a non-executive director for ASX-listed companies Anatara Lifesciences, Benitec Biopharma and Tissue Therapies.

Following a career with multinational companies Sandoz, Hoffman La Roche and Celltech Group, Ross has over the past 20 years undertaken a number of company startups, turnarounds and exits as a board member on behalf of private equity groups and banks. These include Quadrant Healthcare (sold to Elan); Eden BioDesign (sold to Watson Pharmaceuticals); Phadia (sold to Cinven); SR Pharma (merged with Atugen to form Silence Therapeutics); Allergy Therapeutics (prepared for IPO); and Ark Therapeutics.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!